EyePoint Gestione
Criteri Gestione verificati 4/4
EyePoint Il CEO è Jay Duker, nominato in Jan2023, e ha un mandato di 3.5 anni. la retribuzione annua totale è $ 5.57M, composta da 12.5% di stipendio e 87.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.21% delle azioni della società, per un valore di $ 2.58M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.9 anni e 4.9 anni.
Informazioni chiave
Jay Duker
Amministratore delegato
US$5.6m
Compenso totale
| Percentuale dello stipendio del CEO | 12.50% |
| Mandato del CEO | 3.5yrs |
| Proprietà del CEO | 0.2% |
| Durata media del management | 3.9yrs |
| Durata media del Consiglio di amministrazione | 4.9yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Aggiornamento della narrazione • Jun 25
EYPT: Phase 3 Wet AMD Trials Will Support Bullish 2026 Upside
Analysts have reiterated their $37.00 price target on EyePoint, citing updated assumptions around very large revenue growth, a profit margin near 19.6% and a forward P/E of about 65.6x as support for keeping the valuation framework broadly unchanged. What's in the News for EyePoint The Independent Data Safety Monitoring Committee completed its third scheduled review of EyePoint's pivotal Phase 3 program for DURAVYU in wet age-related macular degeneration and recommended that the LUGANO and LUCIA trials continue as planned with no protocol changes.Aggiornamento della narrazione • Jun 05
EYPT: Phase 3 Wet AMD Readouts In 2026 Will Drive Future Upside
Analysts have raised EyePoint's price target to $35 from $31, reflecting updated assumptions about significant early revenue growth, slightly higher profit margin expectations, and a lower anticipated future P/E multiple. What's in the News EyePoint is approaching top-line data from its pivotal Phase 3 DURAVYU trials for wet age-related macular degeneration, with the first readout expected to begin in August 2026 and a second pivotal readout about two months later, according to recent news reports.Aggiornamento della narrazione • May 20
EYPT: Phase 3 Eye Disease Program Will Drive Future Upside Potential
Narrative Update on EyePoint Analysts have adjusted the average price target on EyePoint to $37.00 from $37.17. This change reflects recent upward target revisions into the $29 to $35 range as they consider updated Q4 results, progress on Duravyu programs, and the inclusion of the Phase 3 diabetic macular edema program in their valuation work.Seeking Alpha • May 14
EyePoint: DURAVYU's Durability Could Drive Significant Upside
Summary EyePoint is rated a clear BUY, with central-case DCF modeling indicating roughly 2x upside from current levels. DURAVYU, EYPT's lead candidate for wet AMD and DME, has demonstrated a compelling durability profile in Phase 2 and could benefit from a large, high-turnover wet AMD market if confirmed. Probability-adjusted DCF values DURAVYU at ~$2.9B pre-dilution, with a final equity value of ~$2.3B and ~$27/share after an estimated 20% dilution. Key risks include a ~39% chance of Phase 3 failure, regulatory complexities as a drug-device, and commercial adoption uncertainty amid evolving competition. Read the full article on Seeking AlphaAggiornamento della narrazione • May 04
EYPT: Phase 3 DME Pivotal Program Will Drive Future Upside Potential
Analysts have raised EyePoint's average price target by $6, from $29 to $35, citing updated post-Q4 estimates, the inclusion of the Phase 3 diabetic macular edema program in valuation, and refreshed views on the Duravyu programs. Analyst Commentary Recent Street research reflects a more constructive stance on EyePoint, with several firms updating their valuation frameworks after the Q4 report and program updates.Aggiornamento della narrazione • Apr 19
EYPT: Phase 3 Diabetic Macular Edema Program Will Underpin Future Upside Potential
Narrative update on EyePoint The fair value estimate for EyePoint edges down slightly to $37.17 from $37.42, even as analysts lift published price targets to a range of $29 to $35. They cite updated models after Q4 results, inclusion of the Phase 3 diabetic macular edema program, and refreshed assumptions around the Duravyu programs.Aggiornamento della narrazione • Apr 04
EYPT: Phase 3 Diabetic Macular Edema Program Will Drive Further Upside
Analysts have lifted EyePoint's implied upside in their models, with recent Street price targets moving from a prior range of about $23 to $31 up to $29 to $35, citing updated estimates after Q4 results, the inclusion of the Phase 3 diabetic macular edema program in valuations, and progress across Duravyu programs. Analyst Commentary Bullish Takeaways Bullish analysts are marking up their price targets into a US$29 to US$35 range, which indicates higher expectations around execution and value creation after the recent Q4 update.Aggiornamento della narrazione • Mar 20
EYPT: Phase 3 Diabetic Macular Edema Trials Will Support Further Upside
Narrative Update on EyePoint Analysts have lifted the average price target on EyePoint by about $0.33 to $37.42 as recent research updates incorporate Phase 3 diabetic macular edema expectations and refreshed estimates following the Q4 report. Analyst Commentary Recent research updates on EyePoint focus on refreshed valuation work after the Q4 report and the inclusion of specific pipeline programs in analysts’ models.Aggiornamento della narrazione • Mar 06
EYPT: Phase 3 Diabetic Macular Edema Program Will Drive Future Upside
Analysts have raised their average price target for EyePoint to approximately $37 per share, up from about $36. They attribute this change to updated assumptions following the Q4 results, including the integration of the Phase 3 diabetic macular edema program and revised expectations for the Duravyu franchise.Aggiornamento della narrazione • Feb 19
EYPT: Rebrand And Refined Profit Outlook Will Support Future Upside
Analysts now set a refreshed price target for EyePoint at $36.08, with the update linked to modest adjustments in the discount rate, profit margin expectations, and future P/E assumptions. What's in the News On December 8, 2025, EyePoint Pharmaceuticals, Inc.Articolo di analisi • Feb 04
EyePoint, Inc.'s (NASDAQ:EYPT) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors
The EyePoint, Inc. ( NASDAQ:EYPT ) share price has softened a substantial 27% over the previous 30 days, handing back...Aggiornamento della narrazione • Jan 19
EYPT: Phase 3 Safety Progress And Rebrand Will Support Future Upside
Analysts have raised their price target on EyePoint to reflect updated assumptions on profit margin and future P/E. The new target is now approximately $36.08 per share.Aggiornamento della narrazione • Jan 05
EYPT: Recent Capital Raise And Lock Ups Will Support Future Upside
Analysts have slightly raised their price target on EyePoint to US$36.08, with the modest adjustment tied to unchanged fair value assumptions and very small tweaks to inputs like discount rate, revenue growth, profit margin and future P/E expectations. What's in the News EyePoint Pharmaceuticals, Inc.Aggiornamento della narrazione • Dec 20
EYPT: Phase 3 Ocular Trial Progress Will Drive Future Upside Potential
Analysts have raised their price target on EyePoint from approximately $34.42 to $36.08 per share. This reflects increased confidence in the company’s significantly higher projected revenue growth, despite a modestly higher discount rate and slightly lower forecast profit margins and future valuation multiples.Articolo di analisi • Dec 12
After Leaping 38% EyePoint, Inc. (NASDAQ:EYPT) Shares Are Not Flying Under The Radar
EyePoint, Inc. ( NASDAQ:EYPT ) shareholders would be excited to see that the share price has had a great month, posting...Articolo di analisi • Sep 06
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Looks Just Right With A 32% Price Jump
Despite an already strong run, EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) shares have been powering on, with a gain...Aggiornamento della narrazione • Aug 15
Phase III Trials In Wet AMD Will Expand Market Reach
EyePoint Pharmaceuticals’ consensus price target remained unchanged at $34.42, as strong Phase 2 data and operational improvements offset in-line clinical progress in the development of Duravyu. Analyst Commentary Completion of enrollment in the second Phase 3 LUCIA study for Duravyu.Articolo di analisi • Jun 16
After Leaping 47% EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Are Not Flying Under The Radar
The EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) share price has done very well over the last month, posting an...Articolo di analisi • May 03
Is EyePoint Pharmaceuticals (NASDAQ:EYPT) In A Good Position To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Nuova narrazione • Mar 27
DURAVYU Phase III Trials Will Accelerate Market Entry
Expedited Phase III trial progress and robust patent protection could maximize long-term revenue and margin potential for DURAVYU.Articolo di analisi • Mar 09
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Full-Year Results: Here's What Analysts Are Forecasting For This Year
Shareholders of EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) will be pleased this week, given that the stock price is...Articolo di analisi • Feb 26
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) May Have Run Too Fast Too Soon With Recent 30% Price Plummet
EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) shareholders that were waiting for something to happen have been dealt a...Seeking Alpha • Jan 30
EyePoint: A Risky 'Buy' Ahead Of Key Readout For Long-Acting Eylea Rival
Summary EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections required compared to Eylea and Vabysmo. Positive Phase 2 DME data and ongoing Phase 3 studies suggest significant upside potential, though past mixed results and heavy competition raise risks. Recent fundraising and a new manufacturing facility indicate strong commitment, but the company's financial health and market skepticism remain concerns. I maintain a "risky buy" rating, believing in the potential for substantial gains if pivotal studies succeed, despite the inherent risks and competition. Read the full article on Seeking AlphaArticolo di analisi • Dec 13
EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) 29% Share Price Plunge Could Signal Some Risk
EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) shares have had a horrible month, losing 29% after a relatively good...Seeking Alpha • Nov 14
EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity
Summary EyePoint Pharmaceuticals' lead product, EYP-1901, shows promising phase 2 results for wet AMD and DME, with one phase 3 trial ongoing and one more planned for 2025. EYP-1901 demonstrated strong safety, and efficacy, and reduced treatment burden, positioning it as a potential long-term solution for retinal diseases. Despite a failed NPDR trial, positive DME data suggest potential for targeting more severe diabetic retinopathy, enhancing the investment thesis. EyePoint's financials are robust with a cash runway into 2027, but risks include phase 3 trial outcomes and competition from entrenched anti-VEGF therapies. Read the full article on Seeking AlphaArticolo di analisi • Oct 29
Revenues Not Telling The Story For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Shares Rise 52%
EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) shares have had a really impressive month, gaining 52% after a shaky...Articolo di analisi • Sep 13
EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Intrinsic Value Is Potentially 38% Above Its Share Price
Key Insights The projected fair value for EyePoint Pharmaceuticals is US$12.22 based on 2 Stage Free Cash Flow to...Seeking Alpha • Aug 29
EyePoint Pharmaceuticals - After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)
Summary EyePoint Pharmaceuticals' Duravyu shows promise as a long-acting therapy for Wet AMD, potentially rivaling Regeneron's Eylea with its six-month dosing frequency. Positive Phase 2 Davio study data boosted EyePoint's stock but concerns remain about efficacy, financial strength, competition, and patient/physician adoption. A recent NPDR study failure caused a significant stock drop, but upcoming Phase 3 Wet AMD and Phase 2 DME data could provide new catalysts for gains. Despite risks, I upgrade EyePoint to "Buy" due to potential price volatility and multiple upcoming data catalysts that could drive significant gains. Read the full article on Seeking AlphaArticolo di analisi • Aug 15
These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat
One thing we could say about the analysts on EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) - they aren't optimistic...Articolo di analisi • Aug 09
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
As you might know, EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) last week released its latest second-quarter, and...Articolo di analisi • Jun 19
Some Confidence Is Lacking In EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) As Shares Slide 27%
Unfortunately for some shareholders, the EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) share price has dived 27% in...Seeking Alpha • May 06
EyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)
Summary EyePoint Pharmaceuticals, Inc. stock surged following positive Phase 2 trial outcomes in wet AMD, showing non-inferiority to Eylea. Despite success in wet AMD, 1901 showed disappointing results in an NPDR trial, failing its primary endpoint. Financially, EyePoint is sound with a healthy current ratio and sufficient cash runway, yet facing significant future costs. Investment recommendation: Downgrade EYPT to "Sell" due to high risks and competitive pressures, despite some positive trial results. Read the full article on Seeking AlphaArticolo di analisi • Mar 31
More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%
EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) shares have had a horrible month, losing 26% after a relatively good...Seeking Alpha • Feb 20
EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time
Summary EyePoint Pharmaceuticals' EYP-1901 drug for wet AMD showed positive results in Phase 2 clinical trials, potentially offering a lower-cost and more effective treatment option. The company's proprietary Durasert E technology delivers drugs directly to the eye, maximizing efficacy and minimizing side effects. The company's financials show a decent cash runway, but with high cash burn and premium valuation, financial stability is a concern. Despite promising technology and pipeline, EyePoint Pharmaceuticals' high valuation suggests its stock's potential upside is already reflected in the price. Therefore, I think EYPT is a "hold" for now. Read the full article on Seeking AlphaArticolo di analisi • Feb 05
Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%
Despite an already strong run, EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) shares have been powering on, with a gain...Articolo di analisi • Jan 29
Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, EyePoint Pharmaceuticals fair value estimate is US$36.54...Articolo di analisi • Dec 18
Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 194% But Growth Is Lacking
EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) shareholders would be excited to see that the share price has had a...Articolo di analisi • Dec 13
These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat
Today is shaping up negative for EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) shareholders, with the analysts...Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$272m |
| Dec 31 2025 | US$6m | US$696k | -US$232m |
| Sep 30 2025 | n/a | n/a | -US$206m |
| Jun 30 2025 | n/a | n/a | -US$175m |
| Mar 31 2025 | n/a | n/a | -US$147m |
| Dec 31 2024 | US$6m | US$670k | -US$131m |
| Sep 30 2024 | n/a | n/a | -US$104m |
| Jun 30 2024 | n/a | n/a | -US$87m |
| Mar 31 2024 | n/a | n/a | -US$79m |
| Dec 31 2023 | US$3m | US$614k | -US$71m |
| Sep 30 2023 | n/a | n/a | -US$100m |
| Jun 30 2023 | n/a | n/a | -US$106m |
| Mar 31 2023 | n/a | n/a | -US$102m |
| Dec 31 2022 | US$2m | US$515k | -US$102m |
| Sep 30 2022 | n/a | n/a | -US$78m |
| Jun 30 2022 | n/a | n/a | -US$77m |
| Mar 31 2022 | n/a | n/a | -US$67m |
| Dec 31 2021 | US$3m | US$269k | -US$58m |
| Sep 30 2021 | n/a | n/a | -US$54m |
| Jun 30 2021 | n/a | n/a | -US$42m |
| Mar 31 2021 | n/a | n/a | -US$44m |
| Dec 31 2020 | US$53k | n/a | -US$45m |
| Sep 30 2020 | n/a | n/a | -US$40m |
| Jun 30 2020 | n/a | n/a | -US$52m |
| Mar 31 2020 | n/a | n/a | -US$51m |
| Dec 31 2019 | US$80k | n/a | -US$57m |
Compensazione vs Mercato: La retribuzione totale di Jay ($USD 5.57M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 5.13M ).
Compensazione vs guadagni: La retribuzione di Jay è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Jay Duker (67 yo)
3.5yrs
Mandato
US$5,568,352
Compensazione
Dr. Jay S. Duker, M.D., co-founded Hemera Biosciences Inc. and serves as its Executive Director. He serves as Member of Retina Segment Scientific Advisory Board at Aldeyra Therapeutics, Inc. Dr. Duker is t...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 3.5yrs | US$5.57m | 0.21% $ 2.6m | |
| Executive VP & CFO | 6.7yrs | US$2.17m | 0.15% $ 1.8m | |
| Chief Medical Officer | 2.3yrs | US$2.16m | Nessun dato | |
| Chief Scientific Officer | 1.5yrs | Nessun dato | Nessun dato | |
| Chief Legal Officer & Company Secretary | 7.7yrs | Nessun dato | Nessun dato | |
| Chief People Officer & Senior VP of IT | 7.5yrs | Nessun dato | Nessun dato | |
| Senior Vice President | 7.1yrs | US$1.46m | Nessun dato | |
| Chief Regulatory Officer | 4.3yrs | Nessun dato | Nessun dato | |
| Chief Manufacturing Officer | 1.6yrs | Nessun dato | Nessun dato | |
| Chief Commercial Officer | less than a year | Nessun dato | Nessun dato | |
| CEO of AION Diagnostics Ltd | no data | US$225.94k | Nessun dato |
3.9yrs
Durata media
59.5yo
Età media
Gestione esperta: Il team dirigenziale di EYPT è considerato esperto (durata media dell'incarico 3.9 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 3yrs | US$5.57m | 0.21% $ 2.6m | |
| CEO of AION Diagnostics Ltd | no data | US$225.94k | Nessun dato | |
| Independent Non-Executive Chairman | 8.1yrs | US$368.27k | 0.016% $ 189.8k | |
| Independent Director | 7yrs | US$339.69k | 0% $ 0 | |
| Co- Chairman of Scientific Advisory Board | 4.9yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 4.9yrs | Nessun dato | Nessun dato | |
| Director | 7.8yrs | US$310.94k | 0.026% $ 309.0k | |
| Member of Scientific Advisory Board | 4.9yrs | Nessun dato | Nessun dato | |
| Independent Director | 4yrs | US$332.19k | 0.046% $ 555.9k | |
| Co-Chair of Scientific Advisory Board | 4.9yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 4.9yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 4.9yrs | Nessun dato | Nessun dato |
4.9yrs
Durata media
67yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di EYPT sono considerati esperti (durata media dell'incarico 4.9 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/07 14:54 |
| Prezzo dell'azione a fine giornata | 2026/07/07 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
EyePoint, Inc. è coperta da 22 analisti. 12 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Colleen Kusy | Baird |
| Andrew D'Silva | B. Riley Securities, Inc. |
| Timothy Chiang | Capital One Securities, Inc. |